Stock Markets July 29, 2026 04:24 AM

Gerresheimer Shares Jump After Sale of Two Plastic Packaging Units to Apax Partners

Deal valued at about €1.5 billion incl. debt and proceeds expected to target roughly €1.9 billion of company debt; Goldman Sachs revealed as a major shareholder

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
GXIG

Gerresheimer AG shares climbed sharply after the Düsseldorf-based pharmaceutical packaging firm agreed to sell its U.S. Centor unit and its global Primary Packaging Plastics business to Apax Partners for an enterprise value of about €1.5 billion including debt. The two divisions generated roughly €570 million in revenue last year, employ around 2,400 people across 16 production sites, and the proceeds are expected primarily to be applied to the company’s approximately €1.9 billion debt load. A regulatory filing also showed Goldman Sachs holds a roughly 19-20% voting stake in the company.

Gerresheimer Shares Jump After Sale of Two Plastic Packaging Units to Apax Partners
GXIG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Gerresheimer agreed to sell Centor and its Primary Packaging Plastics division to Apax Partners for an enterprise value of approximately €1.5 billion including debt.
  • The two units generated about €570 million in revenue last year and employ roughly 2,400 people across 16 production sites, and proceeds are expected to be used primarily to reduce the company's approximately €1.9 billion debt burden.
  • A regulatory filing showed Goldman Sachs holds a roughly 19-20% voting stake in Gerresheimer; the announcement drove a company-specific stock rally of +12.4% with shares reaching an intraday high of €31.95.

Gerresheimer AG saw a pronounced share-price rebound after it announced an agreement to divest two of its plastic packaging operations to private equity firm Apax Partners for a combined enterprise value of approximately €1.5 billion, including debt. The disclosure triggered a +12.4% intraday gain, sending the stock to €30.08 and prompting an intraday high of €31.95.

The transaction covers two business units: Centor, the U.S.-based manufacturer of prescription drug packaging systems, and the group’s Primary Packaging Plastics division, which operates on a global basis. Together those units reported about €570 million in revenue in the prior year and employ roughly 2,400 people distributed across 16 production sites.

Company management and market participants have framed the sale as a central element of Gerresheimer’s balance-sheet repair. The proceeds from the divestment are expected to be directed primarily toward reducing the company’s outstanding debt, which stands at about €1.9 billion and had weighed on investor sentiment in recent months.

Investor confidence was bolstered further by a regulatory filing made public the same day showing that Goldman Sachs holds a significant voting stake in Gerresheimer of roughly 19-20%. That institutional position was cited as reinforcement for the restructuring path the company is pursuing.

The broader market backdrop was relatively calm during the session, with U.S. indices essentially flat. Market observers noted the move in Gerresheimer’s stock was driven by company-specific news rather than a broader market impulse. The CEO had flagged the sale of Centor as a priority as recently as the June 2026 earnings call, and today's announcement represented formal execution of a transaction that had been anticipated by investors.

Shares had been trading at multi-year lows prior to the announcement, with a 52-week trough of €14.83. That depressed price level left the stock particularly sensitive to positive corporate developments. Taken together, the confirmed asset sale at a significant valuation, the clear pathway to debt reduction it provides, and the disclosure of increased institutional ownership combined to produce one of the sharpest single-day rallies the stock has seen in recent memory.


Market reaction snapshot

  • Share move: +12.4% to €30.08, intraday high €31.95.
  • Transaction value: ~€1.5 billion enterprise value including debt.
  • Divested revenues and footprint: ~€570 million in revenue last year; ~2,400 employees across 16 sites.
  • Balance sheet focus: Proceeds expected to be used primarily to reduce ~€1.9 billion of debt.
  • Institutional ownership: Goldman Sachs holds a roughly 19-20% voting stake, per regulatory filing.

Risks

  • High debt burden - the company's approximately €1.9 billion of debt has weighed on investor sentiment and remains a central financial constraint until proceeds are applied.
  • Share-price sensitivity - trading near multi-year lows, including a 52-week low of €14.83, has made the stock particularly reactive to company-specific developments.
  • Reliance on the transaction to achieve debt reduction - the intended use of proceeds is to pay down debt, so successful completion and allocation of funds is critical to the restructuring outcome.

More from Stock Markets

Goldman Upgrade Sends Swissquote Shares Upward; Valuation, Earnings Catalyst Cited Jul 29, 2026 Endesa Shares Jump After Strong H1 2026 Results, Guidance Lift Jul 29, 2026 Bureau Veritas Shares Jump as H1 Results Outperform and Guidance Is Raised Jul 29, 2026 Nexi Shares Rise After H1 Results Beat Expectations and Management Reaffirms Guidance Jul 29, 2026 Elia Shares Retreat After H1 2026 Results; Guidance Reaffirmation and Rising Debt Weigh Jul 29, 2026